Announced

US WorldMeds to acquire four cell therapy assets from Adaptimmune for $55m.

Synopsis

US WorldMeds, a pharmaceutical company, agreed to acquire four cell therapy assets from Adaptimmune, a biopharmaceutical company that develops T cell therapies against cancer, for $55m. "We were the first company to obtain a marketing authorization for an engineered TCR T-cell therapy, TECELRA, and we have a second cell therapy, lete-cel, with approval anticipated in 2026. However, given the financial situation of the Company, it is clear that securing the right strategic option was critical to maximize value for all of our stakeholders and importantly ensure our patients continue to receive TECELRA. After an extensive review of all strategic alternatives available to Adaptimmune we are convinced that this transaction represents the best path forward for Adaptimmune, our patients and stakeholders," Adrian Rawcliffe, Adaptimmune CEO.

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

All rights reserved. Copyright © 2025 Datasite

MergerLinks - US WorldMeds to acquire four cell therapy assets from Adaptimmune for $55m.